CMR Surgical Secures $400M from Stryker with Exclusive Acquisition Option

CMR Surgical, a Cambridge, UK-based global medical device company focused on robotic-assisted surgery, has received approximately $400 million in preferred equity from Stryker. The investment, dated October 12, 2026, is part of a strategic alliance between the two companies and includes significant commercial and acquisition terms.

Deal Structure

The transaction is structured as a Series C+ round led by Stryker, with Stryker as the sole listed investor. Beyond the capital, the alliance grants Stryker US sales rights for CMR Surgical's products and an exclusive option to acquire the company. This structure gives Stryker a substantial strategic position in CMR Surgical while preserving the option to pursue full ownership.

What CMR Surgical Does

CMR Surgical develops robotic-assisted surgery systems. Its Versius system is used for minimally invasive soft-tissue procedures in hospitals worldwide. The company is also developing next-generation surgical robotics. The Versius platform positions CMR Surgical in the competitive surgical robotics market, where systems are deployed across hospital networks globally.

Why This Matters for Acquisition Watchers

The exclusive option to acquire is the central feature of this deal for anyone tracking M&A activity in medical devices. A $400 million preferred equity investment paired with US sales rights and an acquisition option represents a staged path to potential full ownership by Stryker. For strategic acquirers in surgical robotics, this transaction signals a model where a larger medtech player secures commercial access and a call option on an emerging platform rather than acquiring outright at the outset.

Key Facts

Company: CMR Surgical
Headquarters: Cambridge, UK
Focus: Robotic-assisted surgery; Versius system for minimally invasive soft-tissue procedures
Round type: Series C+
Funding amount: Approximately $400 million
Currency: USD
Funding date: October 12, 2026
Lead investor: Stryker
Investors: Stryker
Deal terms: Preferred equity; US sales rights; exclusive option to acquire the company

Context

The strategic alliance structure — capital plus commercial rights plus an acquisition option — is a notable template for medtech partnerships. It allows Stryker to participate in CMR Surgical's US commercial trajectory while retaining the right to consolidate ownership. For CMR Surgical, the investment provides capital alongside a commercial partner with US market reach. The transaction is dated October 12, 2026.